[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=3ec1958b2aae390a76eb1ce4083b5ce16ba2f262aafedfd60c9d963759769929",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733244120,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "id": 131778024,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=3ec1958b2aae390a76eb1ce4083b5ce16ba2f262aafedfd60c9d963759769929"
    }
  },
  {
    "ts": null,
    "headline": "Harding Loevner Global Developed Markets Equity Q3 2024 Report",
    "summary": "Global markets advanced during the third quarter of 2024, with all regions posting gains. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=c425dbcba77923799cf4937ae9d3ebb720fc26b0c088ec8944d5b08b8510b85d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733226300,
      "headline": "Harding Loevner Global Developed Markets Equity Q3 2024 Report",
      "id": 131755093,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1921110478/image_1921110478.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Global markets advanced during the third quarter of 2024, with all regions posting gains. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=c425dbcba77923799cf4937ae9d3ebb720fc26b0c088ec8944d5b08b8510b85d"
    }
  },
  {
    "ts": null,
    "headline": "CRISPR Therapeutics: Strong Balance Sheet Supports Ambitious Plans Amid Slow Growth",
    "summary": "CRISPR Therapeutics' Q3 saw reduced expenses and slow Casgevy launch, resulting in a revenue miss. Read why I am neutral on CRSP stock.",
    "url": "https://finnhub.io/api/news?id=1c9fae705e13f82859dce9481acb5efe70fbfa75bf1e277f38e2f67e9ccbc1a8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733195479,
      "headline": "CRISPR Therapeutics: Strong Balance Sheet Supports Ambitious Plans Amid Slow Growth",
      "id": 131748412,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2155873777/image_2155873777.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "CRISPR Therapeutics' Q3 saw reduced expenses and slow Casgevy launch, resulting in a revenue miss. Read why I am neutral on CRSP stock.",
      "url": "https://finnhub.io/api/news?id=1c9fae705e13f82859dce9481acb5efe70fbfa75bf1e277f38e2f67e9ccbc1a8"
    }
  }
]